WOVEN-PLANET/CA-RENOVO
28.9.2021 14:03:03 CEST | Business Wire | Press release
Woven Planet Holdings, Inc. (“Woven Planet”), a subsidiary of Toyota Motor Corporation (“Toyota”), announced the acquisition of Renovo Motors, Inc. (“Renovo”), a pioneering Silicon Valley-based automotive operating system developer. Renovo develops specialized software, which will advance Woven Planet’s mission to enable the most programmable vehicles on the planet with Arene and realize the broader vision of “Mobility to Love, Safety to Live.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005589/en/
The acquisition will add depth to Woven Planet’s resources, particularly for Arene, Woven Planet’s open vehicle development platform, by:
- bolstering their elite team with top-tier engineers who have deep expertise in building a complete software-defined vehicle infrastructure stack
- providing a platform and software that are proven to work across multiple original equipment manufacturer (OEM) platforms, well-aligned with the goal of establishing a hardware-agnostic operating system
- bringing a robust, established technology ecosystem of industry partners
Following on the heels of recent acquisitions made this year, Renovo complements Woven Planet’s strategy to bring together world-class talent and expertise in automated driving technology, next-generation mapping, and vehicle operating systems, ensuring that Woven Planet can power the future of mobility.
Comment from Nikos Michalakis, Senior Vice President of Software Platform,
Woven Planet Holdings:
“The acquisition of Renovo supports Woven Planet's work in transforming worldwide mobility. A key part in delivering our ‘Mobility to Love, Safety to Live’ vision is to enable the most programmable vehicles on the planet – opening vehicle programming to everyone by simplifying vehicle software development and increasing deployment frequency without compromising safety and security. With Renovo having deep roots in the space, we immediately recognized the opportunity and inherent value of the company. The technical and cultural fit could not have been better and all of us are excited to bring our expertise and technology together to power a new era of automotive technology.”
Comment from Christopher Heiser, CEO, Renovo Motors:
“We are in awe with what the Woven Planet team has been building – and are thrilled to join them in creating holistic mobility solutions that will truly benefit humankind. We are united around a singular goal to connect the most ubiquitous software and automotive technology in the industry. In Woven Planet and Toyota, we've found partners committed to doing exactly what we have always wanted to do on a global scale, and that’s a great feeling.”
About Woven Planet Holdings
Woven Planet Group represents a carefully curated blend of expertise and resources dedicated to bringing the vision of “Mobility to Love, Safety to Live” to life. Through innovations and investments in automated driving, robotics, smart cities, and more, we are transforming how humankind lives, works, and moves. We exist to design, build, and deliver secure, connected, and sustainable mobility solutions that benefit all people worldwide. Founded in 2018 as Toyota Research Institute - Advanced Development (“TRI-AD”), Woven Planet is composed of four complementary companies: Woven Planet Holdings, Woven Core, Woven Alpha, and Woven Capital.
For more information, please visit: https://www.woven-planet.global/
About Renovo Motors
Renovo is an award-winning automotive software company and creator of the first commercially available data-management platform that enables automakers to continuously learn from their production vehicles. Renovo’s “Complete Loop” approach allows those automakers to delight their customers with vehicles that get smarter, become safer, increase in performance, and grow in reliability through every day of ownership. From ADAS and infotainment feature improvements to resolving critical safety and potential warranty issues, Renovo makes every mile a vehicle drives 10X more valuable as every mile is used to make the product, your organization, and its teams better.
For more information, please visit: www.renovo.auto
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom